Abstract:Shuaiwei Song, 1– 5, &ast Xintian Cai, 1– 5, &ast Junli Hu, 1– 5 Qing Zhu, 1– 5 Di Shen, 1– 5 Huimin Ma, 1– 5 Yingying Zhang, 1– 5 Rui Ma, 1– 5 Wenbo Yang, 1– 5 Jing Hong, 1– 5 Delian Zhang, 1– 5 Nanfang Li 1– 5 1 Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, 830001, People's Republic of China; 2 Xinjiang Hypertension Institute, Urumqi, Xinjiang, 830001, People's Republic of China; 3 NHC Key Laboratory of Hypertension Clinical Research, Urumqi, Xinjiang, 830001, People's Republic of China; 4 Key Laboratory of Xinjiang Uygur Autonomous Region "Hypertension Research Laboratory", Urumqi, Xinjiang, 830001, People's Republic of China; 5 Xinjiang Clinical Medical Research Center for Hypertension (Cardio-Cerebrovascular) Diseases, Urumqi, Xinjiang, 830001, People's Republic of China &astThese authors contributed equally to this work Correspondence: Nanfang Li, Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region, No. 91 Tianchi Road, Urumqi, Xinjiang, 830001, People's Republic of China, Tel +86 8,564,818, Email Objective: While the role of aldosterone in bone metabolism is well established, the specific effects of the widely used aldosterone antagonist, spironolactone, on bone health are not fully understood. This study aimed to investigate the effects of spironolactone on osteoporosis and future fracture risk in middle-aged and elderly hypertensive patients, revealing its potential benefits for bone health. Methods: Propensity score matching was employed in this study to create matched groups of spironolactone users and non-users at a 1:4 ratio. We investigated the association between spironolactone use and the risk of osteoporosis using multivariate logistic regression analysis. Furthermore, we conducted multivariate linear regression analysis to explore the relationship between cumulative dosage and the FRAX score. Subgroup analysis was also performed to assess the effects under different stratification conditions. Results: In both pre-match and post-match analyses, multivariable logistic regression revealed a significant reduction in the risk of osteoporosis in the spironolactone usage group (pre-match: odds ratios [OR] 0.406, 95% confidence interval [CI], 0.280– 0.588; post-match: OR 0.385, 95% CI, 0.259– 0.571). Furthermore, post-match multivariable linear regression demonstrated a clear negative correlation between cumulative spironolactone dosage and the FRAX score. Subgroup analyses consistently supported these findings. Conclusion: This study offers evidence supporting the significant positive impact of the antihypertensive drug spironolactone on bone health, resulting in a substantial reduction in the risk of osteoporosis and future fractures in hypertensive patients. Future research should consider conducting large-scale, multicenter, randomized controlled trials to further investigate the long-term effects of spironolactone on bone health in hypertensive patients. Keywords: hypertensive, spironolactone, aldosterone, osteoporosis, FRAX score Osteoporosis is a common systemic bone disease that results in weakened bones and an increased risk of fractures. 1 Hypertension and osteoporosis are two prevalent chronic diseases that often co-occur in middle-aged and older adults. 2 Globally, the reported incidence rate of hypertension is approximately 31%, while the incidence rate of osteoporosis can be as high as 21%. 3,4 As life expectancy increases, the incidence rates of both hypertension and osteoporosis are expected to rise, underscoring the growing healthcare challenge posed by these conditions in an aging global population. 5,6 Hypertension is a risk factor for osteoporosis and osteoporotic fractures, significantly impacting morbidity and mortality in both men and women. 7,8 While lifestyle interventions are crucial for managing blood pressure (BP), pharmacological treatments play a more prominent role in reducing BP and the risk of atherosclerotic cardiovascular disease. Various types of antihypertensive medications are available, including angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), and spironolactone, all of which are well-known inhibitors of the renin-angiotensin-aldosterone system (RAAS) and have demonstrated effective blood pressure control. Interestingly, an increasing body of cellular and animal research evidence suggests that localized activation of RAAS in bone tissue may contribute to osteoporosis. 9–11 Effective preventi -Abstract Truncated-

Efficacy and Safety of Low-dose Spironolactone in Elderly Patients With Refractory Hypertension

Effects of Spironolactone on Dialysis Patients with Refractory Hypertension: a Randomized Controlled Study.

Low Dose Spironolactone Alleviates Cardiac Remolding in Patients with NYHA Daass Ⅰ - Ⅱ Heart Failure

Effect of Spironolactone on Some Neurohormonal Factors in Elderly Patients Suffering Cardiac Insufficiency Secondary to Hypertension

Efficacy and Safety of Low-dose Spironolactone for Chronic Kidney Disease in Type 2 Diabetes

Effects of small dose of spironolactone on the patients with isolated systolic hypertension in community

Association between dosing of spironolactone and outcomes in heart failure with preserved ejection fraction patients combined with chronic kidney disease------Balance of efficacy and risk

Retrospective study on the short-term efficacy of different doses of Spironolactone in patients with heart failure of ischemic cardiomyopath and the influence of ventricular remodeling markers

A systematic review and meta-analysis of effects of spironolactone on blood pressure, glucose, lipids, renal function, fibrosis and inflammation in patients with hypertension and diabetes

Safety and Efficacy of Spironolactone in Dialysis-Dependent Patients: Meta-Analysis of Randomized Controlled Trials

The risks and benefits of spironolactone use in heart failure with a reduced left ventricular ejection fraction and chronic kidney disease

Long-Term Effects of Spironolactone on Kidney Function and Hyperkalemia-Associated Hospitalization in Patients with Chronic Kidney Disease

Evaluation of the safety and tolerability of spironolactone in patients with heart failure and chronic kidney disease

Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial

Combined therappy of captopril and spironolactone for refractoroy congestive heart failure

Effects of Spironolactone on Plasma Level of BNP and Cardiac Function in CHF Patients

The Clinical Efficacy and Safety of Valsartan in Treatment of Patients with Essential Hypertensive

Effectiveness of Spironolactone in Reducing Osteoporosis and Future Fracture Risk in Middle-Aged and Elderly Hypertensive Patients

Spironolactone Improves the All-Cause Mortality and Re-Hospitalization Rates in Acute Myocardial Infarction with Chronic Kidney Disease Patients

Efficacy and safety of a low-sodium diet and spironolactone in patients with stage 1-3a chronic kidney disease: a pilot study

The effect of spironolactone on some neurohormonal factors in patients suffering cardiac insufficiency secon-dary to dilated cardiomyopathy